New asthma inhaler version tested in kids: same drug, different delivery

NCT ID NCT07433569

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study tests two versions of the asthma inhaler Symbicort (budesonide/formoterol) in children aged 4 to 12 with asthma. The goal is to see how much of the drug gets into the blood with each version and whether they are safe. Fifteen children will take single doses of both the new Aerosphere and the standard pMDI inhaler. The results will help doctors understand if the new version works similarly in kids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: budesonide and formoterol (combination inhaler)
What this could lead to: If successful, this could show that a new inhaler version delivers the same asthma control with similar drug levels in children, offering an alternative treatment option.
What could go wrong: This is a very early (Phase 1) study with only 15 children, so results may not apply broadly. It focuses on drug levels in the blood, not on how well asthma symptoms are controlled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Research Site

Long Beach, California, 90815, United States
Research Site

Miami, Florida, 33175, United States
Research Site

Lafayette, Louisiana, 70508, United States
Research Site

Toledo, Ohio, 43617, United States
Research Site

Boerne, Texas, 78006, United States
Research Site

El Paso, Texas, 79903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.